Market Overview

UPDATE: MLV & Co. Downgrades Aastrom Biosciences to Hold on Continued Disappointing Enrollment

Related ASTM
Earnings Scheduled For November 13, 2014
Aastrom Biosciences Announces Plans To Change Name To Vericel Corporation And Move Headquarters To Cambridge, Massachusetts

In a report published Wednesday, MLV & Co. analyst downgraded the rating on Aastrom Biosciences (NASDAQ: ASTM) from Buy to Hold, and lowered the price target from $5.50 to $1.50.

In the report, “At the forefront of investors minds has been Aastrom's enrollment progress in their Phase III trial of ixmyelocel-T, conducted under a Special Protocol Assessment (SPA), to test whether the autologous cell therapy can prevent amputation in patients with critical limb ischemia (CLI) and severe peripheral artery disease (PAD). As of March 2013, only 40 patients were enrolled, meaning that only 14 additional patients were enrolled since 3Q:12. The enrollment goal is 594 patients. While the company guides to changes being implemented to augment future enrollment, we are no longer projecting ixmyelocel-T launching in the CLI market by 2017.”

Aastrom Biosciences closed on Tuesday at $1.20.

Latest Ratings for ASTM

DateFirmActionFromTo
Oct 2013Maxim GroupDowngradesBuyHold
Mar 2013Ascendiant CapitalDowngradesStrong BuyBuy
Mar 2013Ascendiant CapitalMaintainsBuy

View More Analyst Ratings for ASTM
View the Latest Analyst Ratings

Posted-In: MLV & Co.Analyst Color Downgrades Analyst Ratings

 

Related Articles (ASTM)

Around the Web, We're Loving...

Get Benzinga's Newsletters